Of note, our study indicates that the anti-cancer effect is synergized by cotreatment with Herceptin, an ERBB2-targeted monoclonal antibody, plus Grb7 knockdown in ERBB2+ breast cancers [5], reflecting the tight correlation between Grb7 and ERBB2 in cancer progression and treatment. This evidence concerns the gene ERBB2 and breast carcinoma.